Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 23729168)

1.

Notch3 is activated by chronic hypoxia and contributes to the progression of human prostate cancer.

Danza G, Di Serio C, Ambrosio MR, Sturli N, Lonetto G, Rosati F, Rocca BJ, Ventimiglia G, del Vecchio MT, Prudovsky I, Marchionni N, Tarantini F.

Int J Cancer. 2013 Dec 1;133(11):2577-86. doi: 10.1002/ijc.28293. Epub 2013 Jun 26.

2.

MS4A8B promotes cell proliferation in prostate cancer.

Ye L, Yao XD, Wan FN, Qu YY, Liu ZY, Shen XX, Li S, Liu XJ, Yue F, Wang N, Dai B, Ye DW.

Prostate. 2014 Jun;74(9):911-22. doi: 10.1002/pros.22802. Epub 2014 Apr 30.

PMID:
24789009
3.

Correlation between overexpression of EpCAM in prostate tissues and genesis of androgen-dependent prostate cancer.

Xu Y, Zhao H, Hou J.

Tumour Biol. 2014 Jul;35(7):6695-700. doi: 10.1007/s13277-014-1892-2. Epub 2014 Apr 8.

PMID:
24705864
4.

Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression.

Alaña L, Sesé M, Cánovas V, Punyal Y, Fernández Y, Abasolo I, de Torres I, Ruiz C, Espinosa L, Bigas A, Y Cajal SR, Fernández PL, Serras F, Corominas M, Thomson TM, Paciucci R.

Mol Cancer. 2014 Mar 31;13:74. doi: 10.1186/1476-4598-13-74.

5.

Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.

Lin HP, Lin CY, Hsiao PH, Wang HD, Sheng Jiang S, Hsu JM, Jim WT, Chen M, Kung HJ, Chuu CP.

PLoS One. 2013 Dec 5;8(12):e82625. doi: 10.1371/journal.pone.0082625. eCollection 2013.

6.

Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.

Ruscica M, Magni P, Steffani L, Gatto F, Albertelli M, Rametta R, Valenti L, Ameri P, Magnaghi V, Culler MD, Minuto F, Ferone D, Arvigo M.

Mol Cell Endocrinol. 2014 Feb 15;382(2):860-70. doi: 10.1016/j.mce.2013.10.027. Epub 2013 Nov 5.

PMID:
24211300
7.

PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.

Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM, Lê Cao KA, Winterford C, Coward JI, Ling MT; Australian Prostate Cancer BioResource, Craik DJ, Parton RG, Russell PJ, Hill MM.

Oncogene. 2014 Jul 3;33(27):3561-70. doi: 10.1038/onc.2013.315. Epub 2013 Aug 12.

PMID:
23934189
8.

Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.

Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, Torre E, Supuran CT, Chiarugi P.

Cell Cycle. 2013 Jun 1;12(11):1791-801. doi: 10.4161/cc.24902. Epub 2013 May 8.

9.

The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.

Hirai K, Nomura T, Yamasaki M, Inoue T, Narimatsu T, Chisato Nakada PD, Yoshiyuki Tsukamoto PD, Matsuura K, Sato F, Moriyama M, Mimata H.

Urol Oncol. 2014 Feb;32(2):101-9. doi: 10.1016/j.urolonc.2012.09.005. Epub 2013 Feb 9.

PMID:
23403204
10.

Peroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells.

Papi A, Storci G, Guarnieri T, De Carolis S, Bertoni S, Avenia N, Sanguinetti A, Sidoni A, Santini D, Ceccarelli C, Taffurelli M, Orlandi M, Bonafé M.

PLoS One. 2013;8(1):e54968. doi: 10.1371/journal.pone.0054968. Epub 2013 Jan 25.

11.
12.

Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.

Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A.

PLoS One. 2012;7(10):e47440. doi: 10.1371/journal.pone.0047440. Epub 2012 Oct 15.

13.

Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.

Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki Y, Miyazaki K.

Am J Clin Pathol. 2012 Oct;138(4):535-44.

14.

Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.

Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li Y, Banerjee S, Padhye S, Sarkar FH.

PLoS One. 2012;7(8):e43726. doi: 10.1371/journal.pone.0043726. Epub 2012 Aug 27.

15.

Hypoxia increases CX3CR1 expression via HIF-1 and NF‑κB in androgen-independent prostate cancer cells.

Xiao LJ, Chen YY, Lin P, Zou HF, Lin F, Zhao LN, Li D, Guo L, Tang JB, Zheng XL, Yu XG.

Int J Oncol. 2012 Nov;41(5):1827-36. doi: 10.3892/ijo.2012.1610. Epub 2012 Aug 27.

PMID:
22941344
16.
17.

Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.

Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL, Visakorpi T.

Oncogene. 2012 Oct 11;31(41):4460-71. doi: 10.1038/onc.2011.624. Epub 2012 Jan 23.

PMID:
22266859
18.

Chronic hypoxia induces androgen-independent and invasive behavior in LNCaP human prostate cancer cells.

Yamasaki M, Nomura T, Sato F, Mimata H.

Urol Oncol. 2013 Oct;31(7):1124-31. doi: 10.1016/j.urolonc.2011.12.007. Epub 2012 Jan 5.

PMID:
22226664
19.

Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.

Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, Pennella A, Ventimiglia G, Barucci R, Piscazzi A, Prudovsky I, Landriscina M, Marchionni N, Tarantini F.

Mol Cancer Res. 2012 Feb;10(2):230-8. doi: 10.1158/1541-7786.MCR-11-0296. Epub 2011 Dec 15.

20.

L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.

Chung LC, Tsui KH, Feng TH, Lee SL, Chang PL, Juang HH.

Am J Physiol Cell Physiol. 2012 Feb 15;302(4):C676-85. doi: 10.1152/ajpcell.00180.2011. Epub 2011 Nov 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk